Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026
Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026
Company Deals

Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader

Fineline Cube Jan 27, 2026
Company Deals

Boehringer Ingelheim Licenses Simcere’s SIM0709 Bispecific for Inflammatory Bowel Disease

Fineline Cube Jan 27, 2026
Policy / Regulatory

China Drug Administration Implementation Regulations Set for May 2026 Launch

Fineline Cube Jan 28, 2026
Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Fineline Cube Jan 28, 2026
Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Fineline Cube Jan 28, 2026
Company Drug

Sino Biopharmaceutical Ltd Secures Exclusive Rights for Generic Everolimus in China

Fineline Cube Jan 4, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced that...

Company Deals

Kexing Pharmaceutical Enters Global Licensing Agreement with Xiling Lab for Eribulin Generic

Fineline Cube Jan 4, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with...

Company Deals

Bio-Thera Solutions Grants Macter International Exclusive Rights to Avzivi in Pakistan and Afghanistan

Fineline Cube Jan 4, 2024

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biopharmaceutical company, has announced a licensing and commercialization agreement...

Company Deals

Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH

Fineline Cube Jan 4, 2024

Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou...

Company Drug

Sciwind Biosciences’ Ecnolgutide Shows Promising Phase III Results in Type 2 Diabetes Treatment

Fineline Cube Jan 4, 2024

Sciwind Biosciences Co., Ltd, a China-based pharmaceutical company, has released the latest topline Phase III...

Company Deals

JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China

Fineline Cube Jan 3, 2024

JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...

Company Drug

InventisBio’s KRAS G12C Inhibitor Garsorasib NDA Accepted for Review by China’s NMPA

Fineline Cube Jan 3, 2024

InventisBio (Shanghai) Co., Ltd (SHA: 688382), a China-based pharmaceutical company, has announced that the New...

Company Deals

Frontage Laboratories Expands European Footprint with Acquisition of Accelera’s DMPK Businesses

Fineline Cube Jan 3, 2024

Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou,...

Company Drug

AstraZeneca and Sanofi’s RSV Prevention Drug Beyfortus Approved by China’s NMPA

Fineline Cube Jan 3, 2024

AstraZeneca (AZ, NASDAQ: AZN) and Sanofi (NASDAQ: SNY), co-development partners in the pharmaceutical industry, have...

Company Deals

China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease

Fineline Cube Jan 3, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend...

Company Drug

Ascletis Pharma’s ASC41 Shows Promising Results in Phase II NASH Study

Fineline Cube Jan 3, 2024

Ascletis Pharma Inc. (HKG: 1672), a Chinese pharmaceutical company, has announced positive interim results from...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Approval for NSCLC Perioperative Treatment

Fineline Cube Jan 3, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company Drug

Roche’s Phesgo and Faricimab Receive NMPA Approvals for Breast Cancer and nAM

Fineline Cube Jan 3, 2024

The National Medical Products Administration (NMPA) has granted separate approvals for two distinct drugs from...

Company Deals

WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services

Fineline Cube Jan 3, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

BeiGene’s Tislelizumab Secures 12th Indication Approval in China for HCC First-Line Treatment

Fineline Cube Jan 3, 2024

BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received approval...

Company Drug

BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments

Fineline Cube Jan 3, 2024

The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...

Company Deals

Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization

Fineline Cube Jan 3, 2024

Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...

Company Deals

Orient Gene Biotech to Acquire Hangzhou Laihe Biotech, Expanding POCT and AI in Healthcare

Fineline Cube Jan 3, 2024

Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to...

Company Deals

Shanghai Teogen Life Technology and China National Medical Device Form Strategic Partnership

Fineline Cube Jan 3, 2024

Shanghai Teogen Life Technology Co., Ltd, a Chinese-based company, has announced a strategic partnership with...

Company Deals

Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management

Fineline Cube Jan 3, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China,...

Posts pagination

1 … 370 371 372 … 615

Recent updates

  • China Drug Administration Implementation Regulations Set for May 2026 Launch
  • Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials
  • Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal
  • IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform
  • Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China Drug Administration Implementation Regulations Set for May 2026 Launch

Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.